BMB, represented by its Founder, Prof. Michael Malkoch, attended the ATiO 2024 meeting in Berlin to engage with top-tier surgeons and established medtech companies in the orthopedic field. As one of fourteen carefully selected startups focusing on future solutions in Orthobiologics, BMB showcased its unique platform, Bonevolent™ - injectable implants personalized by surgeons for patients' fractures. Bonevolent™ is centered around blue-light curable composites with the aim of advancing orthopedic care through tailored solutions, starkly differentiating itself from the current standard of metal implants.
Comments